Elite Pharmaceuticals, Inc., a health care company based in Northvale, United States, has been actively engaged in the research, development, licensing, and manufacturing of both new and generic oral controlled-release pharmaceutical products. The company’s focus spans across various therapeutic areas, including cardiovascular, antidiabetic, anti-infective agents, as well as cough and cold preparations. Currently, Elite Pharmaceuticals is advancing its portfolio with pain products that are in clinical trials, showcasing its commitment to addressing diverse medical needs.
As of December 8, 2025, the company’s stock is traded on the OTC Bulletin Board, with a close price of $0.52. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $0.82 on June 17, 2025, and a 52-week low of $0.27 on April 6, 2025. This fluctuation reflects the dynamic nature of the pharmaceutical industry and the market’s response to the company’s ongoing developments and strategic initiatives.
With a market capitalization of $556.64 million, Elite Pharmaceuticals maintains a price-to-earnings ratio of 40.08, indicating investor expectations and the company’s growth potential. The company’s financial metrics highlight its position within the health care sector, particularly in the pharmaceuticals industry, where innovation and regulatory approvals play critical roles in shaping market performance.
Founded in 1998, Elite Pharmaceuticals has established itself as a key player in the development of controlled-release pharmaceuticals. The company’s strategic focus on both new and generic products allows it to cater to a broad spectrum of healthcare needs, leveraging its expertise in controlled-release technology to enhance patient outcomes.
For more detailed information about Elite Pharmaceuticals’ activities, offerings, and strategic direction, stakeholders and interested parties are encouraged to visit the company’s website at www.elitepharma.com . This platform provides comprehensive insights into the company’s ongoing projects, clinical trials, and future prospects within the competitive landscape of the pharmaceutical industry.
